To report the first case of myocarditis in a patient with metastatic castration-resistant prostate cancer (mCRPC) treated with a combination of nivolumab, an anti-programmed cell death protein 1 antibody, and PROSTVAC, a vector-based therapeutic prostate cancer vaccine targeting prostate specific antigen (PSA). This evidence concerns the gene PDCD1 and prostate carcinoma.